Shanying International Holdings (600567.SH): The actual controller's share increase plan is extended.
Shanying International Holdings (600567.SH) announced that Mr. Wu Mingwu, the company's actual controller, plans to increase his holdings of the company's A-shares through the centralized bidding trading method via the Shanghai Stock Exchange trading system from November 18, 2026 to November 20, 2026, with a total increase amount of no less than RMB15 million. Because the relevant parties are planning a major matter involving the company and the company's shares are suspended from trading, the implementation of this share increase plan is postponed, with the postponement period being 3 trading days from the date the company's shares resume trading.
Shanying International Holdings (600567.SH) announced that Mr. Wu Mingwu, the company's actual controller, plans to increase his holdings of the company's A-shares through the centralized bidding trading method via the Shanghai Stock Exchange trading system between November 18, 2026 and November 20, 2026, with a total increase amount of no less than RMB15 million. Because the relevant parties are planning a major matter involving the company and the company's shares are suspended from trading, the implementation of this share increase plan is postponed, with the postponement period being 3 trading days from the date the company's shares resume trading.
Related Articles

Yinchuan Xinhua Commercial (600785.SH) has cumulatively repurchased 8.85% of its shares, spending approximately RMB300 million.

GRAND PHARMA (00512): Globally Innovative Nebulized Inhalant GPN01564 for the Treatment of Respiratory Syncytial Virus Approved to Initiate Phase I Clinical Study

Aotop Technology (688845.SH) IPO priced at RMB18.18 per share, subscription opens on November 23.
Yinchuan Xinhua Commercial (600785.SH) has cumulatively repurchased 8.85% of its shares, spending approximately RMB300 million.

GRAND PHARMA (00512): Globally Innovative Nebulized Inhalant GPN01564 for the Treatment of Respiratory Syncytial Virus Approved to Initiate Phase I Clinical Study

Aotop Technology (688845.SH) IPO priced at RMB18.18 per share, subscription opens on November 23.






